MARKET

PRQR

PRQR

Proqr Therapeuti
NASDAQ
0.7556
-0.0103
-1.34%
After Hours: 0.7800 +0.0244 +3.23% 16:02 09/29 EDT
OPEN
0.7600
PREV CLOSE
0.7659
HIGH
0.7850
LOW
0.7510
VOLUME
153.21K
TURNOVER
0
52 WEEK HIGH
9.09
52 WEEK LOW
0.5300
MARKET CAP
53.92M
P/E (TTM)
-0.8148
1D
5D
1M
3M
1Y
5Y
--HC Wainwright Adjusts Price Target on ProQR Therapeutics to $1.50 From $2, Reiterates Buy Rating
--HC Wainwright Adjusts Price Target on ProQR Therapeutics to $1.50 From $2, Reiterates Buy Rating
MT Newswires · 08/15 09:56
Raymond James Bullish On This Penny Stock's Reprioritized Pipeline
Raymond James upgraded ProQR Therapeutics N.V. (NASDAQ: PRQR) to Outperform based on a high conviction that "RNA editing" emerges as an impactful field of therapeutics in coming years. Related: This Penny Stock Biotech Offloads Eye Portfolio To Focus On RN...
Benzinga · 08/12 18:05
ProQR upgraded at Raymond James on RNA-editing platform
Raymond James has upgraded ProQR Therapeutics N.V. (NASDAQ:PRQR...
Seekingalpha · 08/12 12:45
--Cantor Fitzgerald Downgrades ProQR Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.80 From $3.50
--Cantor Fitzgerald Downgrades ProQR Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.80 From $3.50
MT Newswires · 08/12 12:03
--Raymond James Upgrades ProQR Therapeutics to Outperform From Market Perform; Price Target is $2
--Raymond James Upgrades ProQR Therapeutics to Outperform From Market Perform; Price Target is $2
MT Newswires · 08/12 04:20
--Chardan Research Downgrades ProQR Therapeutics to Neutral From Buy on Further Restructuring, Wind-Down of Inherited Retinal Disease Programs; $2 Price Target Removed
--Chardan Research Downgrades ProQR Therapeutics to Neutral From Buy on Further Restructuring, Wind-Down of Inherited Retinal Disease Programs; $2 Price Target Removed
MT Newswires · 08/12 04:11
This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing
ProQR Therapeutics N.V. (NASDAQ: PRQR) said it would look for a partner to take the company’s ophthalmology portfolio further into clinical trials. The company had said that after disappointing data from its pivotal Phase 2/3 Illuminate trial for lead cand...
Benzinga · 08/11 18:48
ProQR says EU regulator seeks additional trial for lead candidate
Dutch biotech ProQR Therapeutics N.V. (NASDAQ:PRQR) annou...
Seekingalpha · 08/11 11:26
More
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.